ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 322

Immune Response to Porphyromonas Gingivalis Citrullinated α-Enolase Cross-Reacts with Human α-Enolase in Polyarticular JIA Patients

Peggy Lee1, Rebecca Howsmon2, Claire Murphy2, Sarah Ringold3 and Anne M. Stevens4, 1School of Dentistry, University of Washington, Seattle, WA, 2Center for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA, 3Pediatrics, Seattle Children's Hospital, Seattle, WA, 4Pediatrics, University of Washington, Seattle, WA

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Citrulline and juvenile idiopathic arthritis (JIA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Pediatric Rheumatology - Pathogenesis and Genetics

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Antibodies recognizing cyclic citrullinated peptides (CCP) are highly specific for rheumatoid arthritis (RA) and polyarticular juvenile idiopathic arthritis (poly JIA), and may both predict and contribute to early onset and an aggressive disease course. Risk factors for RA, including the HLA-DRB1 shared epitope (SE) and smoking, are associated with higher levels of anti-CCP antibodies. It is unknown what the natural targets of anti-CCP are, or how they are generated.  P. gingivalis, associated with gingivitis and periodontitis, expresses a citrullinated protein, α-enolase, with homology to human α-enolase, and thus is a strong candidate for the autoantigen bound by anti-CCP antibodies.  The P. gingivalis α-enolase may serve as a link between oral inflammation induced by P. gingivalis and arthritis. The pathogenesis of JIA may thus involve molecular mimicry between epitopes from citrullinated bacterial and human, triggering autoimmunity in genetically susceptible individuals.

Methods:

Anti-citrullinated enolase peptide antibodies (anti-CEP) were quantified by ELISA in plasma from 20 RF+ poly JIA patients ages 7.1-18.5 years and 20 age- and sex-matched controls. Target peptides were selected based on previously identified immunodominant epitopes in adult RA patients, and included P. gingivalis CEP citrulline- versus arginine-containing sequences and the human CEP peptide homologs. Citrullinated vimentin and citrullinated non-immunogenic CEP were negative controls.  Antibodies to CCP were assayed by QUANTA Lite CCP3.1 IgG/IgA ELISA.

Results:

Antibodies to CCP were detected in all 20 RF+ JIA patients and in one of 20 controls, though at low titer.   Antibodies to Hu-CEP were detected in 9 JIA patients (45%). All patients with anti-Hu-CEP antibodies also carried Abs to PG-CEP.  A tight correlation was found between anti-PG CEP and anti-Hu CEP (R2=0.70), suggesting cross-reactivity between antibodies.  Patients with the DRB1 shared epitope (n=12) were no more likely to carry anti-Hu-CEP (50%) or anti-PG-CEP (58%) than those without the shared epitope (n=8, 38%, 50%).  No differences were found between patients and controls in control peptide responses, which were all low.  Only weak correlations were detected between anti-CEP and age of onset or disease activity as assessed by ESR, CRP, active joint count, loss of range of motion, MD assessment or CHAQ. 

Conclusion:

A high proportion of patients with RF+ poly JIA develop Abs to citrillinated proteins, which were not detected in healthy children.  The coincidental occurrence of anti-Hu-CEP and anti-PG CEP suggest an etiologic role for P. gingivalis infection in poly JIA.


Disclosure:

P. Lee,
None;

R. Howsmon,
None;

C. Murphy,
None;

S. Ringold,
None;

A. M. Stevens,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/immune-response-to-porphyromonas-gingivalis-citrullinated-%ce%b1-enolase-cross-reacts-with-human-%ce%b1-enolase-in-polyarticular-jia-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology